Managing director & CEO Siddharth Mittal says is de-risking supply chain as Trump tariffs loom. 'We’re scenario-mapping but there’s a limit to how much we can do,' he tells Moneycontrol ...

Biocon's reported net profit for the quarter was ₹31 crore, compared to ₹660 crore in Q1FY25. Excluding one-time gains from a ...

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth ...

Our Bureau, New Delhi Friday, August 8, 2025, 13:30 Hrs [IST] Biopharmaceutical major Biocon Ltd has reported a 95 per cent decline i ...

Biocon reported a 342% YoY increase in its net profit before exceptional items, reaching Rs 31 crore in Q1FY26, primarily driven by its robust biosimilars business.

Biocon reported a 95% year-on-year drop in net profit for Q1, despite a 15% increase in operating revenue. The decline was offset by a like-for-like profit after tax growth of 65%.

The drugmaker is ultimately planning a $200 million effort to manufacture three insulin products at its plant at 1 Civica Way ...

Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard ...

AM, GIFT Nifty futures were trading 30 points lower at 24,642, indicating a negative start for markets. Markets in ...

Indian equity benchmarks, BSE Sensex and NSE Nifty, are set to open lower on the last day of the week, tracking mixed cues ...

Demand for weight-loss and diabetes drugs seen global surge, CEO says move will come once patents begin to expire next year ...

Eris Lifesciences is positioning itself to capture a significant share of India’s human insulin market following Novo Nordisk ...